Figure 9. Neddylation induces SHP2 inactivation to potentiate the effect of immunotherapy in vivo.

(A and B) Tumor sizes in the indicated mice (10 mg/kg anti-PDL1 antibody or isotype control, n = 6). Mice with tumor volumes of less than 2,000 mm³ are considered to be surviving (A). The survival of mice was monitored (B). (C and D) Tumor sizes of indicated mice (10 mg/kg anti-PDL1 antibody or isotype control, n = 6) (C). Tumor images and weights of indicated mice (10 mg/kg anti-PDL1 antibody or isotype control, n = 6). Scale bars: 10 mm (D). (E) Representative images of MC38 tumor sections (n = 3). H&E staining was conducted, and necrosis areas were measured. Fluorescent multiplex immunohistochemistry was conducted, and apoptosis was measured by cleaved caspase-3 staining. Scale bars: 1 mm. (F) ELISA analysis of MC38 tumor homogenates (n = 6). Data are represented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, P > 0.05. One-way ANOVA followed by Tukey’s post hoc test (C, E, D); 2-way ANOVA followed by Tukey’s post hoc test (F); Kaplan-Meier log-rank test (B).